Long-term survival in trial of medium-titre Edmonston-Zagreb measles vaccine in Guinea-Bissau: five-year follow-up

Epidemiol Infect. 1994 Apr;112(2):413-20. doi: 10.1017/s0950268800057836.


A trial of protective efficacy which compared medium-titre Edmonston-Zagreb (EZ) measles vaccine (10(4.6) p.f.u.) from the age of 4 months with the standard Schwarz (SW) measles vaccine given from the age of 9 months was started in an urban community in Guinea-Bissau in 1985. Because trials of high-titre measles vaccine have found increased mortality among female recipients, we examined whether EZ medium-titre vaccine was associated with any long-term impact on mortality, suppression of T-cells, or growth. The mortality rate ratio over 5 years of follow-up was 1.12 for EZ children compared with children in the standard group (P = 0.63). Seventy-five percent of the children still residing in the area at 5 years of age took part in an immunological and anthropometric examination. There was no difference in T-cell subsets between the two groups. There was no difference in mid-upper-arm circumference, but EZ children were significantly shorter than the children in the standard group. In conclusion, medium-titre EZ was not associated with reduced survival or persistent immunosuppression.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Body Height
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Growth Disorders / chemically induced*
  • Growth Disorders / diagnosis
  • Growth Disorders / epidemiology*
  • Guinea-Bissau / epidemiology
  • Humans
  • Immune Tolerance / drug effects*
  • Immunization Schedule*
  • Infant
  • Leukocyte Count
  • Malaria / blood
  • Malaria / epidemiology
  • Malaria / parasitology
  • Male
  • Measles Vaccine / adverse effects*
  • Measles Vaccine / classification*
  • Measles Vaccine / immunology
  • Mortality*
  • Proportional Hazards Models
  • Survival Rate
  • T-Lymphocyte Subsets*


  • Measles Vaccine